

RSV Prevention Options for Infants

APRIL 2024

	Maternal Vaccine	Infant Preventive Monoclonal Antibody	Infant Preventive Monoclonal Antibody
Name:	ABRYSVO (RSV preF vaccine)	BEYFORTUS (Nirsevimab)	SYNAGIS (Palivizumab)
Approved for:	Pregnant women for the protection of infants	All infants born during or entering their first RSV season AND Children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season	Infants born preterm (≤ 35 weeks) and who are 6 months or younger at the beginning of RSV season OR Infants with underlying health conditions like BPD or CHD and who are 24 months or younger at the beginning of RSV season
Administered:	During 32 weeks through 36 weeks and 6 days of pregnancy at a health care provider's office or pharmacy	In the hospital after birth before discharge OR In a pediatrician's office	Prior to the start of the RSV season with remaining doses administered monthly throughout the RSV season
How supplied:	3-component kit that requires reconstitution	Pre-filled syringe: 50 mg and 100 mg	Single-dose liquid solution vials: 50 mg per 0.5 mL and 100 mg per 1 mL
More details:	LEARN MORE	LEARN MORE	LEARN MORE

This Document Does Not Provide Medical Advice.

This document is provided for reference and informational purposes only and does not constitute providing medical advice or professional services. The information and internet links/URLs provided are for general informational purposes only. It should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician or other health care worker. Neither the National Coalition for Infant Health nor its employees, members, or any contributor to this document makes any representations, express or implied, concerning the information provided herein or its use. The views expressed herein have no relation to those of any academic, hospital, practice, or other institution with which the authors are affiliated.